AMAL Therapeutics enters clinical collaboration with Boehringer Ingelheim to evaluate ATP128 in combination with BI754091
? AMAL?s lead candidate, ATP128, will be evaluated in combination with Boehringer Ingelheim?s antiPD-1 antibody BI754091 in a Phase Ib trial (?KISIMA-01?)
? Combination will be studied in patients with Microsatellite Stable (MSS) stage IV colorectal cancer
? AMAL retains full development and commercialization rights to ATP128 and the KISIMA technology
platform
Geneva, Switzerland -? AMAL Therapeutics (AMAL), a Swiss biotech developing
novel, peptide-based therapeutic cancer vaccines, today announces that it has entered into a
collaborative agreement with Boehringer Ingelheim. AMAL will conduct an international Phase Ib
clinical study, referred to as KISIMA-01, to evaluate the combination of its lead candidate, ATP128,
with Boehringer Ingelheim?s anti-PD1 compound, BI754091, in Microsatellite Stable (MSS) patients
with stage IV colorectal cancer.
AMAL?s lead candidate, ATP128, is a chimeric recombinant protein designed using AMAL?s
proprietary vaccine technology platform, KISIMA?. ATP128 comprises of a cell penetrating peptide
(CPP) for antigen delivery, a TLR peptide agonist for self-adjuvanticity and a multiple antigenic
domain (Mad). ATP128 is designed to treat colorectal cancer.
The first-in-human (FIH) study will investigate the safety and tolerability of ATP128 as single agent
and in combination with BI754091 as its primary objective whilst the anti-tumor activity and the
characteristics of the immune response will be evaluated as secondary and exploratory objectives.
The clinical study will be sponsored by AMAL while Boehringer Ingelheim will provide the trial with
BI754091. The study results shall be jointly owned. AMAL retains full development and
commercialization rights to ATP128 and the KISIMA technology platform.
?Our strong in-vivo data package for combination therapies demonstrated synergies between ATP128
and immune checkpoint inhibitors, which laid the basis for this first-in-human clinical study. We are
excited to evaluate ATP128 in combination with BI754091 in different patient populations with stage
IV colorectal cancer, and to show the value of our lead candidate and the potential of the KISIMA
platform? said Madiha Derouazi, Chief Executive Officer and founder of AMAL Therapeutics.
The KISIMA-01 study will begin in the second half of 2019.
-EndFor further information, please contact:
AMAL Therapeutics SA
Dr. Madiha Derouazi
Chief Executive Officer
Tel: +41 (0) 22 379 46 88
contact@amaltherapeutics.com
Instinctif Partners (for International and English-speaking media)
Dr Christelle Kerouedan
Tel: +44 (0) 207 457 2020
amaltherapeutics@instinctif